Search Articles

Search for keyword:

Search for author:

Featured Article
Saturday, May 23, 2015

Region Focus

Regulatory translations in CEE

Libor Safar

Translations required as part of the regulatory approval process for medicinal products are, arguably, one of the most exciting areas in the translation industry today. It’s a growth area, and while it’s heavily regulated — or perhaps because of this fact — it is in a state of constant flux.

Not surprisingly, the majority of the pharmaceutical market across Central and Eastern Europe (CEE), which is estimated to be worth in excess of $63 billion, is occupied by global pharmaceutical companies. This applies to both innovative, patented products, as well as generic products, which constitute over half of the market value.

With the high concentration of organizations that exist in the pharmaceutical industry, leading manufacturers from the United States, the European Union (EU) and Japan have the largest share. However, the CEE pharmaceutical markets are also increasingly targeted by smaller companies. These companies tend to make use of rapid access to these markets as a result of their countries’ membership in the EU.

The Russian pharmaceutical market is a special case. It may constitute some two thirds of the whole CEE pharmaceutical market and has its own specific regulations when it comes to ...

To read this entire article you must be a MultiLingual subscriber. For immediate access to the current issue, subscribe to the digital version. Already a subscriber?

Above excerpt taken from the March 2012 issue of MultiLingual published by MultiLingual Computing, Inc., 319 North First Avenue, Suite 2, Sandpoint, Idaho 83864-1495 USA, 208-263-8178, Fax: 208-263-6310. Subscribe

March, 2012